Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06144918 · ClinicalTrials.gov registry record · Phase 2
Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure
A Phase 2 study, sponsored by Skye Bioscience.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT06144918: Completed Phase 2 study, sponsored by Skye Bioscience.
NCT06144918 is a Phase 2 study that has completed, run by Skye Bioscience. The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06144918, a Phase 2 study, has completed, sponsored by Skye Bioscience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test in patients with glaucoma and elevated pressure in the eye. The main questions it aims to answer are: • ability to lower pressure in the eye • safety in the eye and the body of patients with elevated pressure in the eye. Patients will be randomly given either: * 0.5% (5 mg/mL) SBI-100 Ophthalmic Emulsion * 1.0% (10 mg/mL) SBI-100 Ophthalmic Emulsion * Placebo Ophthalmic Emulsion Patients will be tested before starting and will have one drop of the product placed into each eye twice a day for 14 days, by the site and by the patient. At the end of the study, researchers will compare the groups to see if there is a change from before use of SBI-100 Ophthalmic Emulsion to the end of study.
Interventions
- DRUG SBI-100 Ophthalmic Emulsion, 0.5%
- DRUG SBI-100 Ophthalmic Emulsion, 1.0%
- DRUG SBI-100 Ophthalmic Emulsion, Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2024-02-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06144918
The ClinicalTrials.gov registry entry for NCT06144918 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Skye Bioscience, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which SBI-100 Ophthalmic Emulsion, 0.5% is the first listed.
NCT06144918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06144918 about?
NCT06144918 is a clinical study titled "Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure". The goal of this clinical trial is to test in patients with glaucoma and elevated pressure in the eye. The main questions it aims to answer are: • ability to lower pressure in the eye • safety in the eye and the body of patients with elevated pressure in the eye. Patients will be randomly given eith...
What is the current status of trial NCT06144918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2023-11-09. Estimated completion is 2024-02-22.
What interventions are being tested in trial NCT06144918?
The interventions under investigation include: SBI-100 Ophthalmic Emulsion, 0.5% (DRUG), SBI-100 Ophthalmic Emulsion, 1.0% (DRUG), SBI-100 Ophthalmic Emulsion, Placebo (DRUG).
Who is sponsoring clinical trial NCT06144918?
This trial is sponsored by Skye Bioscience, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.